Eyecelerator & ARVO 2025

Eyecelerator & ARVO 2025 Annual Meeting

Visit our Booth #1031

4-8 May 2025

Salt Lake City

Visit our Booth #1031

The future is here: Unlock the power of AI in Clinical Trials and Daily Practice with RetinAI Discovery® - transforming how you work and research

Join us at Eyecelerator and ARVO to learn how AI is transforming Clinical Trials by improving efficiency and patient enrollment. Explore how AI-powered pre-screening platforms are optimizing trial design, accelerating patient recruitment, and boosting trial success.

If you're a Clinician eager to enhance your daily practice, now is the perfect time to explore our cutting-edge AI solutions. Experience streamlined workflows with Discovery CONNECT™, an automated solution that seamlessly synchronizes OCT imaging data and delivers real-time insights to your clinic.

Don’t miss the opportunity to learn from leading experts, engage with innovative solutions, and see how RetinAI is shaping the future of Ophthalmology.

Book a meeting now!

Connect with us at Eyecelerator!

🗓 Friday, 2nd May, 2025 📌 Grand Hyatt Deer Valley in Park City

Make sure to book the meeting in advance by clicking the button below.

CTA Meeting Request Button Meeting Request

‍

Exclusive Satellite Event: Improving Efficiency and Enrollment in Clinical Trials with AI

Hosted in collaboration with Topcon

🗓 Sunday, 4th May, 2025

⏰ 6.00 PM MST I Near the Salt Palace Convention Center, Salt Lake City

Join us for a one-of-a-kind session at ARVO, where leading retina specialists will dive into how AI-powered pre-screening platforms are revolutionizing the efficiency of clinical trials and transforming patient enrollment.

Meet our Speakers

Featuring expert presentations from Dr. SriniVas R. Sadda, Dr. Omer Trivizki, and Dr. David Eichenbaum, this event will showcase groundbreaking data and real-world applications of AI to:

Optimize clinical trial design
Enhance patient recruitment
Improve clinical trial success rates

Don’t miss this exclusive opportunity to engage with top experts, exchange ideas, and gain valuable insights into the future of clinical trials.

Stay tuned! The full program, including venue details, will be available soon!

Limited spots available—sign up now!

Expandable Form

‍

Posters co-authored by RetinAI

See Discovery platform and AI models featured in the following poster presentations from RetinAI's Team and Collaborators

4 May

Impact of acquisition device and quality control on test-retest repeatability of thickness measurements derived from OCT segmentation models

‍
🕐 1:00 PM - 2:45 PM 👉 Add a bookmark in your calendar
📍Machine Learning for Segmentation and Other Applications I Poster Board 577 - A0214
📖 Read the abstract

6 May

Predicting Visual Sensitivity Loss in Eyes with Geographic Atrophy using OCT Imaging and Fundus Autofluorescence

🕐 8:30 AM - 10:15 AM 👉 Add a bookmark in your calendar
📍Clinical Applications in OCT I Poster Board 2793 - A0058
📖 Read the abstract
‍

‍

Translating nascent Geographic Atrophy definition into measurable biomarkers in OCT

🕐 1:15 PM - 3:00 PM 👉 Add a bookmark in your calendar
📍AMD 3 (imaging) I Poster Board 3491 - B0054
📖 Read the abstract

‍

Impact of B-Scan Density on Accuracy of Geographic Atrophy Lesion Measurement in Optical Coherence Tomography

🕐 1:15 PM - 3:00 PM 👉 Add a bookmark in your calendar
📍AMD 3 (imaging) I Poster Board 3508 - B0071
📖 Read the abstract

‍

Automatic OCT segmentation biomarkers for disease staging in Geographic Atrophy

🕐 3:30 PM - 5:15 PM 👉 Add a bookmark in your calendar
📍AI in epidemiology I Poster Board 3862 - B0399
📖 Read the abstract

‍

Presentations using our Discovery Platform

See Discovery platform and AI models featured in the following poster presentations from the industry

‍

5 May

Prediction of success and failure events during the journey of neovascular AMD treatments with anti-VEGF injections: a preliminary analysis.

‍
🕐 3:00 - 4:45 PM
📍 AMD anti-VEGF II
📖 Read the abstract

‍

Analysis of Optical Coherence Tomography Biomarkers in Diabetic Macular Edema: Baseline Characteristics and One-Year Outcomes After Intravitreal Therapy

‍
🕐 8:30 - 10:15 AM
📍 AI in the Retina I
📖 Read the abstract

‍

6 May

Ratio of Photoreceptor to Retinal Pigment Epithelium Atrophy at Baseline and Longitudinal Retinal Pigment Epithelium Atrophy Growth in Age-Related Macular Degeneration

‍
🕐 8:30 - 10:15 AM
📍 Clinical Applications in OCT
📖 Read the abstract

‍

Using artificial intelligence to assess macular edema in retinitis pigmentosa

‍
🕐 8:30 - 10:15 AM
📍 Retinitis Pigmentosa and IRD II
📖 Read the abstract

‍

AI analysis of OCT images from a Phase 1b study of ONL1204 Fas inhibition treatment for geographic atrophy secondary to age-related macular degeneration

‍
🕐 1:15 - 3:00 PM
📍 AMD 3 (imaging) | Poster Board 3461 - B0024
📖 Read the abstract

‍

Final results of the phase 2 BETTER trial using intravitreal ISTH0036, a selective TGF-β2 blocking antisense in nAMD and DME

‍
🕐 3:30 - 5:15 PM
📍 AMD Clinical Research II
📖 Read the abstract

‍

7 May

Correlation Between Contrast Sensitivity Function and OCT Biomarkers Among Patients with AMD

‍
🕐 10:15 - 12:00 PM
📍 AMD 4 (clinical research)
📖 Read the abstract

‍

Comparison of Multilayer Segmentation Thickness Results Between Two OCT Devices Using a Common Automated Algorithm

‍
🕐 10:15 - 12:00 PM
📍 AI in the Retina II
📖 Read the abstract

‍

Protein Changes Associated with Incomplete Response to Anti-VEGF Therapy in Diabetic Macular Edema – Integration of Proteomics and Artificial Intelligence

‍
🕐 2:00 - 3:45 PM
📍 Diabetic Retinopathy Mechanisms and Preclinical Studies
📖 Read the abstract

Sign Up And Receive Our Latest Promotions!